Description

Glipizide Tablets (Gukangni) are a sulfonylurea-class oral antidiabetic compound designed for experimental evaluation of insulin secretion, beta-cell function, and glucose-lowering mechanisms.

This formulation delivers 5mg per tablet, packaged as 12 tablets per blister × 3 blisters (36 tablets total per box), making it suitable for repeated-dose or multi-phase lab protocols. Manufactured by Shandong Lukang Pharmaceutical Group Sihte Co., Ltd., this product meets research-grade standards.

?? For laboratory and investigational use only. Not for human or veterinary administration.

Product Parameters

Mechanism & Research Applications

Glipizide stimulates insulin secretion from functioning pancreatic beta cells. As a second-generation sulfonylurea, it has enhanced binding affinity and lower effective dosage compared to first-generation agents. In lab studies, it is primarily used to investigate:

• Pancreatic beta-cell stimulation models

• Hypoglycemic mechanisms

• Insulin resistance and receptor sensitivity

• Drug interaction research with metformin or DPP-4 inhibitors

This compound is vital in exploring Type 2 diabetes mechanisms, pharmacodynamics of oral antidiabetics, and beta-cell failure progression.

Safety & Handling

• For research and experimental use only

• Not approved for human or animal therapeutic use

• Handle in a controlled lab environment with appropriate PPE

• Dispose of according to biohazard protocols

Research Use Disclaimer

This product is sold strictly for experimental and laboratory research. It is not intended for diagnostic, therapeutic, or clinical use in humans or animals. Only trained professionals should handle or store this compound.